Sector revisions Exelixis, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-09-11 EDT			5-day change	1st Jan Change
56.12 ^USD	-2.28%		-4.90%	+28.04%

09-11	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Inflation Data Release	MT
09-11	Exelixis, Inc. Extends FDA Review Period for Zanzalintinib New Drug Application in Combination with Atezolizumab for Metastatic Colorectal Cancer	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Visibility	Nbr of analysts
EXELIXIS, INC.		16
WUXI APPTEC CO., LTD.		18
ARGENX SE		15
INSMED INCORPORATED		22
WUXI BIOLOGICS (CAYMAN) INC.		24
BIONTECH SE		20
GENMAB A/S		15
PHARMAESSENTIA CORPORATION		8
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.		18
SUMMIT THERAPEUTICS INC.		13
MADRIGAL PHARMACEUTICALS, INC.		16
ARROWHEAD PHARMACEUTICALS, INC.		12
AKESO, INC.		21
CYTOKINETICS, INCORPORATED		20
VAXCYTE, INC.		9
IMMUNITYBIO, INC.		4
REMEGEN CO., LTD.		16
BELITE BIO, INC		9
SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.	-	-
Average		15
Weighted average by Cap.		17

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!